The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation

Mowatt G, Scotland G, Boachie C, Cruickshank M, Ford JA, Fraser C, Kurban L, Lam TB, Padhani AR, Royle J, Scheenen TW, Tassie E
Record ID 32011000656
English
Authors' objectives: This review aims to assess the diagnostic accuracy of MRS and enhanced MRI techniques (DCE-MRI, DW-MRI) and the clinical effectiveness and cost-effectiveness of strategies involving their use in aiding the localisation of prostate abnormalities for biopsy in patients with prior negative biopsy in whom there remains a clinical suspicion that they are harbouring malignancy.
Authors' recommendations: Study assessing the diagnostic accuracy of magnetic resonance spectroscopy (MRS) and enhanced magnetic resonance imaging (MRI) techniques in aiding the localisation of prostate abnormalities for biopsy found that MRS had higher sensitivity and specificity than T2-weighted magnetic resonance imaging (T2-MRI) but produced no definitive conclusions on the cost-effectiveness of using different MRS/MRI sequences.
Details
Project Status: Completed
Year Published: 2013
URL for published report: http://www.hta.ac.uk/2355
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Magnetic Resonance Imaging
  • Magnetic Resonance Spectroscopy
  • Prostatic Neoplasms
Contact
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name: journals.library@nihr.ac.uk
Contact Email: journals.library@nihr.ac.uk
Copyright: 2013 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.